Next Article in Journal
131I–Tositumomab in Lymphoma
Previous Article in Journal
Preparation with Recombinant Humanized Thyroid-Stimulating Hormone before Radioiodine Ablation after Thyroidectomy: A Systematic Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 16
Issue 5
10.3747/co.v16i5.464
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer

by
F. Kraeber–Bodéré
1,2,
D. M. Goldenberg
3,
J. F. Chatal
4,5,* and
J. Barbet
2,4
1
Nuclear Medicine Department, University Hospital, Nantes, France
2
Cancer Research Center, University of Nantes, INSERM, Nantes, France
3
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Belleville, NJ, USA
4
Arronax Cyclotron, University of Nantes, Nantes, France
5
GIP Arronax, 1 rue Aronnax, BP 10112, 44817 Nantes-Saint- Herblain CEDEX, France
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2009, 16(5), 3-8; https://doi.org/10.3747/co.v16i5.464
Submission received: 4 June 2009 / Revised: 8 July 2009 / Accepted: 12 August 2009 / Published: 1 September 2009

Excerpt

Note: In lieu of an abstract, this is an excerpt from the first page.

Medullary thyroid carcinoma (mtc) is a rare cancer (less than 8% of all thyroid cancers) that occurs both as a familial and as a sporadic disease [...]
Keywords: pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin pretargeted radioimmunotherapy; medullary thyroid cancer; calcitonin

Share and Cite

MDPI and ACS Style

Kraeber–Bodéré, F.; Goldenberg, D.M.; Chatal, J.F.; Barbet, J. Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. Curr. Oncol. 2009, 16, 3-8. https://doi.org/10.3747/co.v16i5.464

AMA Style

Kraeber–Bodéré F, Goldenberg DM, Chatal JF, Barbet J. Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. Current Oncology. 2009; 16(5):3-8. https://doi.org/10.3747/co.v16i5.464

Chicago/Turabian Style

Kraeber–Bodéré, F., D. M. Goldenberg, J. F. Chatal, and J. Barbet. 2009. "Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer" Current Oncology 16, no. 5: 3-8. https://doi.org/10.3747/co.v16i5.464

APA Style

Kraeber–Bodéré, F., Goldenberg, D. M., Chatal, J. F., & Barbet, J. (2009). Pretargeted Radioimmunotherapy in the Treatment of Metastatic Medullary Thyroid Cancer. Current Oncology, 16(5), 3-8. https://doi.org/10.3747/co.v16i5.464

Article Metrics

Back to TopTop